



February 11, 2014

## Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2013 Financial Results and Conference Call

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- [Foundation Medicine, Inc.](#) (NASDAQ:FMI) today announced that financial results for the company's fourth quarter and year ended December 31, 2013 will be released on Tuesday, February 25, 2014. The management team will host a conference call discussing the company's financial results and recent developments on Tuesday, February 25, 2014 at 4:30 p.m. ET. The call can be accessed by dialing 1-877-941-4774 (domestic) or 1-480-629-9760 (international) five minutes prior to the start of the call and providing the passcode 4667446.

The live, listen-only webcast of the conference call can be accessed by visiting the investors section of the Foundation Medicine website at [investors.foundationmedicine.com](#). A replay of the webcast will be available shortly after the conclusion of the call and archived on the company's website for two weeks following the call.

### About Foundation Medicine

[Foundation Medicine](#)<sup>®</sup> (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, [FoundationOne](#)<sup>™</sup> for solid tumors and [FoundationOne](#)<sup>™</sup> Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify the molecular alterations in a patient's tumor and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit [www.FoundationMedicine.com](#) or follow Foundation Medicine on [Twitter](#) (@FoundationATCG).

*Foundation Medicine<sup>®</sup> is a registered trademark, and FoundationOne<sup>™</sup> is a trademark, of Foundation Medicine, Inc.*

### Media Contact:

Pure Communications, Inc.  
Dan Budwick, 973-271-6085  
[dan@purecommunicationsinc.com](mailto:dan@purecommunicationsinc.com)

or

### Investor Contact:

Matt Clawson, 617-418-2283  
[ir@foundationmedicine.com](mailto:ir@foundationmedicine.com)

Source: Foundation Medicine, Inc.

News Provided by Acquire Media